Ipamorelin: Completed Trials, Legal Status, and Where to Buy It (2026)

From Novo Nordisk to Helsinn

The NNC 26-0161 code preserves ipamorelin's origin inside Novo Nordisk's discovery work. Clinical development later moved to Helsinn Therapeutics in the United States, which sponsored two studies in postoperative ileus, the temporary slowing of gastrointestinal recovery after surgery.

That indication was not an arbitrary pick. Alongside the pituitary work, ipamorelin was shown to accelerate gastric emptying through GHS-R1a signalling on cholinergic excitatory neurons, and that effect was demonstrated in a rat model of postoperative ileus. The surgical programme followed the mechanism.

NCT00672074 was a randomized Phase 2 trial sponsored by Helsinn Therapeutics (U.S.). It enrolled 117 participants and was completed in December 2009. The next study expanded the program: NCT01280344 was a Phase 2 dose-finding trial after bowel resection, also sponsored by Helsinn Therapeutics. It enrolled 320 participants and was completed in May 2014.

That sequence matters. This was not a laboratory observation followed by years of inference. A corporate candidate entered multicenter human studies, progressed into a larger dose-finding trial, and reached a completed Phase 2 record.

What the ileus trials found

The first study asked whether ipamorelin could shorten the time until a standardized solid meal was tolerated after bowel resection. Beck and colleagues published the results in the International Journal of Colorectal Disease in 2014.

The median time to the first tolerated meal was 25.3 hours in the ipamorelin arm and 32.6 hours with placebo. The difference did not reach statistical significance, with p = 0.15. The authors reported that ipamorelin was well tolerated, but the study did not meet its primary efficacy endpoint.

The larger dose-finding study was completed, and development did not proceed beyond Phase 2. The published result therefore supplies a clear boundary. Ipamorelin showed enough preclinical rationale to justify a real surgical program, but the measured primary endpoint did not establish an advantage over placebo.

A clean negative result is productive science. It narrows uncertainty, separates a plausible mechanism from a demonstrated clinical outcome, and gives later researchers a firmer starting point than an anecdote or an unfinished pilot could provide. Ipamorelin's record is interesting because the central question was asked properly and answered.

What is the CJC-1295 and ipamorelin combination?

The CJC-1295 and ipamorelin combination pairs a GHRH analog with a selective ghrelin-receptor secretagogue, so the two signals reach the pituitary through separate receptors. It is the most searched ipamorelin pairing by a wide margin, and it is a catalogue pairing rather than a studied clinical regimen. Neither Helsinn Phase 2 trial evaluated ipamorelin alongside CJC-1295. Controlled data on the specific combination is limited, and most of the supporting literature describes GHRH-plus-secretagogue pairings generally rather than this pair.

There is also an identity problem on the CJC-1295 side that a researcher should settle before reading any of that literature. The name covers two different molecules: a version with a drug affinity complex and one without. They have different half-lives and different published records, and vendor labelling is inconsistent about which is in the vial. The CJC-1295 DAC and no-DAC comparison sets out that distinction.

Curo lists the two compounds as a CJC-1295 no DAC and ipamorelin set at $114, 5mg of each. The set ships as two separate vials and is not premixed, which keeps each lot tied to its own certificate.

Regulatory status in 2026

Four separate documents describe ipamorelin's current standing, and each answers a narrower question than the others.

At its October 29, 2024 meeting, FDA's Pharmacy Compounding Advisory Committee considered the free base and acetate forms for the 503A Bulks List. The approved meeting minutes record a vote of 0 yes, 12 no, and 1 abstention for ipamorelin free base, and the same 0 yes, 12 no, and 1 abstention for ipamorelin acetate. The minutes were approved January 15, 2025.

For outsourcing facilities, ipamorelin acetate appears on FDA's list of bulk drug substances that may present significant safety risks under section 503B, in the version updated March 21, 2025. That 503B listing is distinct from the 503A advisory vote.

An enforcement record provides another important distinction. FDA's January 26, 2022 warning letter to Innoveix Pharmaceuticals cites the firm's July 9, 2021 voluntary recall of a compounded sermorelin and ipamorelin injection because of a lack of sterility assurance. The cited issue was the compounded product's sterility assurance, not the outcome of the Phase 2 ileus study.

Sport rules form a separate layer. WADA's 2026 Prohibited List took effect January 1, 2026. Growth hormone secretagogues, including ipamorelin, sit under section S2 and are prohibited at all times, both in and out of competition. One published enforcement example predates that edition: USADA announced a two-year sanction for UFC athlete David Branch after a May 24, 2019 sample contained ipamorelin. His period of ineligibility began July 26, 2019.

Finally, ipamorelin was not among the substances listed for the July 23 and 24, 2026 Pharmacy Compounding Advisory Committee meeting. The Federal Register notice named BPC-157, KPV, TB-500, MOTS-c, emideltide, semax, and epitalon. The later agenda does not add a new ipamorelin vote.

Is ipamorelin legal to buy?

In the United States, ipamorelin is legal to purchase as a research chemical for laboratory use. It is not a controlled substance and does not appear on any DEA schedule as of August 2026. What it also is not: an approved drug, a dietary supplement ingredient, or a compound cleared for human or veterinary use in any form.

Three boundaries define the current legal picture:

1. Research sale is lawful; human-use marketing is not. FDA has repeatedly cited peptide sellers whose sites promote human use, and courts have treated that line seriously. The owner of one vendor, Paradigm Peptides, was sentenced to 70 months in federal prison in July 2026 for selling unapproved and adulterated drugs. The offense was not stocking peptides. It was selling them for human consumption while faking the paperwork.
2. Sport is stricter than law. WADA prohibits growth hormone secretagogues, ipamorelin among them, under section S2 at all times for tested athletes, regardless of the compound's legal status as a research chemical.
3. The compounding route is closed, not open. The October 2024 advisory committee voted 12 to 0 against listing ipamorelin for 503A compounding, and ipamorelin acetate sits on the 503B safety-risk list. No lawful compounded or prescription form exists in the US as of August 2026.

None of this changes how a supplier like Curo operates: ipamorelin is sold strictly for laboratory research, not for human or animal use. Curo's research use only policy covers what that means in practice.

Where to buy ipamorelin for laboratory research

Researchers looking for where to buy ipamorelin face a supplier market that changed sharply in 2025 and 2026. Peptide Sciences closed in March 2026, Amino Asylum went offline after a reported federal raid in June 2025, and Paradigm Peptides ended in a criminal sentencing. Several sites now trade on those dead brand names, so the first check is not price. It is whether the company behind the storefront actually exists. Our guide to the best peptide companies in 2026 covers the current field vendor by vendor.

Five checks separate a documented ipamorelin source from an anonymous one:

1. A lot-specific COA, published before purchase. The certificate should match the exact lot on the vial, not a generic product-page badge. The help center shows how to verify a certificate against your lot.
2. A named, independent laboratory. A COA is only as good as the lab that issued it. Court records in the Paradigm case showed the defendants admitted faking certificates outright, which is the failure mode this check exists to catch.
3. Identity and purity by more than one method. Ipamorelin contains three non-standard residues, including Aib at position 1 and D-2-Nal at position 3. Mis-incorporation at those positions is a real synthesis failure, so HPLC purity alone leaves an identity gap. Look for LC-MS identity confirmation and endotoxin results alongside it.
4. An identifiable company. A legal entity, a real contact route, and consistent policies. A brand name alone is not an identity, and the clone sites trading on dead vendors prove it.
5. Payment with recourse. Card payment carries buyer protection. Venmo, Zelle, and crypto-only checkouts remove it.

Curo stocks ipamorelin in 5mg and 10mg vials and the CJC-1295 no DAC and ipamorelin set in the research catalog. Every lot is tested by an independent laboratory for identity (LC-MS), purity (HPLC), and endotoxin, the full testing standard is documented, and every certificate is publicly readable without an account. Orders are fulfilled from the United States, and payment options include card, crypto, Zelle, and Cash App.

How much does ipamorelin cost?

As of August 2026, research-grade ipamorelin runs roughly $39 to $90 for a 5mg vial and $50 to $115 for a 10mg vial from US suppliers that publish lot-matched, independently issued COAs. Cheaper vials exist, some under $35, but they cluster among suppliers who publish no lot documentation at all or answer with "COA available on request", and an unverified lot is unusable as research material at any price. Curo's ipamorelin is $59 for 5mg and $79 for 10mg, inside the documented tier rather than at the top of it, and the CJC-1295 no DAC and ipamorelin set is $114 for 5mg of each as two separate vials. Compare the documentation attached to the current batch first, then the price. The pre-purchase checklist walks the full sequence.

What an ipamorelin certificate of analysis should show

Ipamorelin is synthesized by many suppliers, so material quality is something a lab confirms rather than assumes. Identity, purity, endotoxin load, and fill accuracy all vary by manufacturer and by lot. A certificate worth relying on shows:

• The exact lot number that appears on the vial.
• The issuing laboratory's name and report identifier.
• HPLC purity with the chromatogram, not a bare percentage.
• Mass-spectrometry identity confirmation against the expected 711.85 g/mol.
• An endotoxin result, since a pure peptide can still carry bacterial contamination from synthesis.
• A way to verify the document independently, through a public lookup or the lab itself. Curo's COA database is open for exactly this reason.

Read each analytical method for the question it answers. LC-MS supports molecular identity. HPLC reports chromatographic purity. Endotoxin testing measures endotoxin burden. Those are the three methods in Curo's quality and testing standard, and no single one of them substitutes for the other two.

A well-tested lyophilized peptide can still be degraded by poor handling after receipt. See storing research peptides and bacteriostatic water for the storage side.

For a broader framework on separating documentation from marketing when comparing suppliers, see how to evaluate research peptide companies and the companion piece on purity claims and COA batch documentation.

Further reading

The tesamorelin development profile offers a neighboring record with a different endpoint and a different regulatory outcome: a growth hormone axis compound that reached an approved drug label.

AOD-9604 followed a similar arc to ipamorelin and then took an unexpected turn: development stopped after a missed obesity endpoint, and the compound reappeared years later under a new name in pain research. That history is set out in the AOD-9604 second career.

A finished trial programme is easier to read than one just beginning. For the opposite end of that arc, MOTS-c entered its first registered administration study in February 2026, with results still pending; the registry picture is mapped in Nine MOTS-c trials, one that administers the peptide.

Frequently asked questions

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts selectively at the GHS-R1a ghrelin receptor. Novo Nordisk developed it under the code NNC 26-0161 and described it in 1998. It is not approved as a drug in any country and is sold in the United States as a research chemical.

Is ipamorelin legal to buy in the US?

Yes, as a research chemical for laboratory use. Ipamorelin is not a controlled substance as of August 2026. It is not approved for human use, no lawful compounded form exists after the October 2024 advisory vote against 503A listing, and WADA prohibits growth hormone secretagogues under section S2 at all times.

Where can a researcher buy ipamorelin?

From suppliers that publish lot-specific, independently issued COAs and operate as identifiable companies. Several well-known vendors closed or faced federal action in 2025 and 2026, and clone sites now trade on their names, so verify the company before the price. Curo lists ipamorelin for laboratory research with every lot's certificate published openly.

How much does ipamorelin cost?

Suppliers that publish lot-matched third-party COAs typically charge $39 to $90 for a 5mg research vial and $50 to $115 for a 10mg vial as of August 2026. Curo's 5mg vial is $59 and the 10mg vial is $79, each with the lot's certificate published before purchase. Vials under that range usually come without verifiable lot documentation.

How much does the CJC-1295 and ipamorelin set cost?

Curo's CJC-1295 no DAC and ipamorelin set is $114 for 5mg of each compound as of August 2026. The two ship as separate vials rather than premixed, so each carries its own lot number and its own published certificate.

Does the CJC-1295 pairing have the same evidence?

No. Catalogue pairings and clinical evidence are different records. The two ileus trials evaluated ipamorelin within their registered study designs, not the common CJC-1295 and ipamorelin combination. The CJC-1295 side also carries an unsettled identity question between its DAC and no-DAC forms.

Did ipamorelin fail its clinical trials?

The published Phase 2 study did not meet its primary efficacy endpoint. It also reported that ipamorelin was well tolerated. Calling that a completed negative result is more precise than framing the entire research program as either a success or a cautionary tale.

Why were the trials about postoperative ileus?

The development program tested whether a growth hormone secretagogue could improve gastrointestinal recovery after bowel surgery. That was the defined pharmaceutical indication behind both Helsinn-sponsored Phase 2 studies.

Is ipamorelin banned in sport?

Yes. WADA prohibits growth hormone secretagogues under section S2 at all times, in and out of competition, and USADA sanctioned a UFC athlete for two years after a 2019 sample contained ipamorelin.

What should a certificate of analysis for ipamorelin show?

Lot-specific identity and purity data from chromatographic and mass-spectrometry methods, plus endotoxin results, tied to the exact lot number on the vial and verifiable through a public lookup. It cannot establish that the material will reproduce a pharmaceutical trial result.